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Abstract: Metal storage disorders (MSDs) are a set of rare inherited conditions with variable clinical
pictures including neurological dysfunction. The objective of this study was, through a systematic
review, to identify the prevalence of Parkinsonism in patients with MSDs in order to uncover
novel pathways implemented in Parkinson’s disease. Human studies describing patients of any
age with an MSD diagnosis were analysed. Foreign language publications as well as animal
and cellular studies were excluded. Searches were conducted through PubMed and Ovid between
April and September 2018. A total of 53 publications were identified including 43 case reports,
nine cross-sectional studies, and one cohort study. The publication year ranged from 1981 to 2018.
The most frequently identified MSDs were Pantothenate kinase-associated neurodegeneration
(PKAN) with 11 papers describing Parkinsonism, Hereditary hemochromatosis (HH) (7 papers),
and Wilson’s disease (6 papers). The mean ages of onset of Parkinsonism for these MSDs were
33, 53, and 48 years old, respectively. The Parkinsonian features described in the PKAN and HH
patients were invariably atypical while the majority (4/6) of the Wilson’s disease papers had a typical
picture. This paper has highlighted a relationship between MSDs and Parkinsonism. However, due to
the low-level evidence identified, further research is required to better define what the relationship is.
Keywords: Parkinson’s disease; Parkinsonism; metal storage disorders; inborn error of metabolism
1. Introduction
Parkinson’s disease (PD) is a common and debilitating neurodegenerative disorder. First described
in 1817 by James Parkinson, PD is a chronic condition distinguished by bradykinesia, rigidity,
postural instability, and resting tremor often described as “pill-rolling.” The clinical features are
due to the loss of dopaminergic neurones located in the pars compacta of the substantia nigra.
Why these neurons are lost is poorly understood. However, numerous studies from animal models
and familial cases of PD have identified that accumulation of cytoplasmic inclusions of alpha-synuclein
(α-synuclein) called Lewy bodies, oxidative stress, and mitochondrial dysfunction may all play
a pathogenic role in their destruction [1,2].
Despite multiple well-documented risk factors suggesting an environmental association such as
well-water drinking, pesticide exposure, head injury, and rural living [3], only increased age carries
sufficient statistical evidence to be causative [4]. Male gender and Caucasian ethnicity were reported
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to increase the risk of PD in research studies while tobacco smoking has been found to be protective.
Therefore, the existence of other aetiological mechanisms not yet identified must be considered.
Parkinsonism is a clinical picture of a tremor, rigidity, bradykinesia, and postural instability
most frequently caused by sporadic PD. However, it has been described in many other conditions.
Parkinsonism can be associated with additional features such as dystonia, early autonomic dysfunction,
a rapidly progressive disease course, or levodopa unresponsiveness [5]. In this instance, it is described
as atypical Parkinsonism since it differs from the typical clinical picture seen in Parkinson’s disease.
Inborn errors of metabolism (IEMs) are a large collection of individually rare but collectively
common inherited conditions [6]. They are a diverse set of conditions that occur as a result of
a monogenic mutation resulting in a deficiency of an enzyme or cofactor [7]. Metal storage disorders
are a large subset of these.
Studies have found that patients with PD have increased levels of iron accumulation in the basal
ganglia compared with healthy controls [8]. Research has also been conducted into the potential
toxic mechanisms of iron causing nigral cell death and leading to PD features in sporadic PD patients
even though it remains unclear whether neuronal death is a direct result of iron accumulation or if
the accumulation is a by-product of dopaminergic cell death [9].
This systematic review aims to identify whether there is a wider pathological link between
PD and metal storage disorders by exploring published accounts of Parkinsonism in patients
with a previously diagnosed metal storage disorder. Identifying other conditions that produce
Parkinsonian-like clinical features may uncover novel pathological mechanisms that contribute to
the development of PD. In addition, this paper will discuss whether the clinical features seen in
the patients with metal storage disorders displaying Parkinsonism are of a typical picture seen in PD
or if they are more similar to atypical Parkinsonism.
2. Materials and Methods
This systematic review was conducted by following the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) 2009 guidance [10].
2.1. Search Terms
Systematic literature searches were conducted in the PubMed and Ovid SP databases including
all published articles prior to the search date. The last search was completed on 6 September, 2018.
The titles and abstracts were searched by combining two search terms (Term A and Term B). Term A
was ‘Parkinson,’ ‘Parkinson’s,’ ‘Parkinsonism,’ or ‘Parkinsonian’ while Term B included each of
the individual metal storage disorders. A list of metal storage disorders was collated from a relevant
review article [11]. A full list of the search terms can be found in Appendix A.
2.2. Inclusion Criteria
Human studies of all designs were considered except review articles. Only publications describing
patients with a definite genomic or biochemical diagnosis of a metal storage disorder were analysed.
Publications reporting adults, children, and infants were all included since metal storage disorders
and Parkinsonian features can present at any age. Cohorts from all nationalities and ethnic backgrounds
were also included.
2.3. Exclusion Criteria
Animal and cellular model studies were excluded as well as autopsy reports. Papers describing
PD patients with MSD associated gene mutations were also excluded unless they had a confirmed
diagnosis of that disorder. Publications written in languages other than English, without whole
text translations available, were excluded. Reviews and letters to editors were also excluded
but the references examined to identify any potentially relevant references that the searches had
omitted were accepted.
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2.4. Selection Process
The publications acquired from the searches were screened in line with the selection criteria by
reading the titles and abstracts to assess relevance. Afterward, full texts were sought for all papers
eligible for inclusion. Two reviewers conducted this screening process to ensure adherence to selection
criteria. Conflicts were resolved through discussion between the reviewers.
2.5. Data Extraction
The primary outcomes extracted from the publications were the type of study, the IEM affecting
the patients reported in the study, and whether the patient had features of typical or atypical
Parkinsonism. Patients were identified as possessing atypical Parkinsonism if there was evidence
of early autonomic dysfunction, a rapidly progressive course, lack of asymmetrical features at
onset, and a poor response to conventional levodopa therapy or a Parkinson-Plus syndrome, as per
the definition in the introduction. Where available, the gender, age of onset of Parkinsonian features,
smoking status, and ethnicity were recorded as secondary outcomes. A breakdown of the data collected
from each individual paper including the clinical picture of the patients can be found in Table A1.
3. Results
In total, 967 publications were identified corresponding to 827 unique articles which underwent
the screening process. Following the title and abstract review, 730 were excluded since they did
not satisfy the inclusion criteria. Following full text screening, a further 53 records were excluded.
Six additional relevant publications were identified from hand searching the reference lists of
the reviews and letters identified in the searches. A total of 50 papers were included in this review.
Figure 1 shows a PRISMA flowchart of the selection process. The final group of articles consisted
of 40 (80.0%) case reports and series, nine (18.0%) cross-sectional studies, and one (2.0%) cohort study
(Table 1). The year of publications ranged from 1981 to 2018 with three (6.0%) papers published before
1990, three (6.0%) papers published in the decade between 1991 to 2000, 12 (24.0%) papers published
from 2001 to 2010, and 32 (64.0%) papers published in the current decade from 2011 to 2018 (Table 1).
Table 1. Characteristics of included publications.
Year of Publication Range 1981–2018
Number of Publications per Decade
Before 1990 3
1991–2000 3
2001–2010 12
2011–2018 32
Type of Study
Cohort study 1
Cross-sectional study 9
Case reports/series 40
Typical Parkinsonism was reported in 16 (32.0%) publications and atypical in 38 (76.0%)
publications, which is shown in Table 2. Of these papers, four described subjects with both typical
and atypical features. Additionally, 173 patients were reported to have Parkinsonism, 86 (49.7%)
were male, and the average age of onset was 35 years old. The ratio of males to females observed
was 0.99:1 (86 males to 87 females). The smoking status was not reported in any of the publications
(Appendix B).
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Figure 1. Prisma flow chart illustrating the search strategy and the selection process.
Pantothenate kinase-associated neurodegeneration (PKAN), which is the most prevalent
neurodegenerative brain iron accumulation (NBIA) disorder, was the most documented metal
storage disorder and was reported in 11 papers. All of these publications described patients
displaying features of atypical Parkinsonism. Three papers also described subjects with typical
Parkinsonian features. Within the 85 PKAN patients reflected by these articles, the mean age of
onset of Parkinsonism was 33 years old. The gender ratio was 1.36:1 with 49 males and 36 females
described. PLA2G6-associated neurodegeneration (PLAN) was another frequently identified
NBIA with three publications identified. Typical parkinsonism features were described by two of these
papers while the remaining publications reported atypical Parkinsonism. Other NBIAs identified
beta-propeller protein-associated neurodegeneration (BPAN) with five publications (four with
atypical Parkinsonism and one with typical features), Kufor-Rakeb Syndrome with five articles
(all atypical, although one described patients with typical features), and mitochondrial-membrane
protein-associated neurodegeneration (MPAN) (three papers describing atypical parkinsonism).
In addition, three publications described atypical features in subjects with neuroferritinopathy and one
paper described a patient with Aceruloplasminemia presenting with features of atypical Parkinsonism.
An additional paper described a subject with atypical features who suffered from an unknown type
of NBIA.
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Table 2. Characteristics of the disorder-related parkinsonism described in the included publications, in order of the number of papers identified.
Condition Metal Involved Brain Region Implicated
Total No. of Papers
(No. Typical, No. Atypical)
No. (% Total) of Male and Female
Patients Described
Average Age of Patients
(Years, Mean± Standard Error)
Panthonase Kinase associated
Neurodegeneration (PKAN)
Iron Basal ganglia (GP, SN) 11 (3;11)
49 M (57.6%)
36 F (42.4%)
33 ± 3.8
Hereditary Haemochromatosis Iron - 7 (4;3)
10 M (71.4%)
4 F (28.6%)
53 ± 3.3
Wilson’s Disease Copper Basal ganglia (PMN, GP) 6 (6;4)
3 M (33.3%)
6 F (66.6%)
46 ± 6.8
Beta-Propeller Protein-Associated
Neurodegeneration (BPAN)
Iron Basal ganglia (SN, GP) 5 (1,4)
3 M (9.7%)
28 F (90.3%)
27 ± 1.1
Kufor-Rakeb Syndrome Iron Basal Ganglia (SN, GP) 5 (1;5)
10 M (90.9%)
1 F (9.1%)
13 ± 0.7
Mitochondrial-Membrane
Protein-Associated
Neurodegeneration (MPAN)
Iron Basal Ganglia (SN, GP) 3 (0;3)
1 M (50.0%)
1 F (50.0%)
25 ± 10.0
Neuroferritinopathy Iron
Cerebellum, Basal ganglia,
motor cortex
3 (0;3) 5 F (100.0%) 61± 17.5
PLA2G6-Associated
Neurodegeneration (PLAN)
Iron Basal ganglia (SN, GP) 3 (2;1)
3 M (60.0%)
2 F (40.0%)
24 ± 5.2
Pseudohypoparathyroidism Calcium
Basal ganglia,
deep white matter
3 (0;3)
1 M (33.3%)
2 F (66.6%)
43 ± 11.8
Fahr Disease Calcium
Basal ganglia, deep white
matter, cerebellum
2 (1;1)
1 M (50.0%)
1 F (50.0%)
56 ± 6.0
Aceruloplasminemia Iron Basal ganglia 1 (0;1)
4 M (80.0%)
1 F (20.0%)
NA
Neurodegenerative Brain Iron
Accumulation (NBIA),
Unknown Type
Iron - 1 (0;1) 1 M (100.0%) 73 ± 0.0
Total - - 50 (16;38)
86 M (49.7%)
87 F (50.3%)
35 ± 1.6
GP = Globus Pallidus, F = Female, M = Male, PMN = Putamen, SN = Substantia Nigra, NA = Not Available.
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After PKAN and NBIAs, the next most reported metal storage disorders were Hereditary
Haemochromatosis (HH) and Wilson’s disease. Seven articles were identified that reported patients
with HH and four papers (57.1%) described typical Parkinsonism. In these publications, 14 subjects
were described including 10 males and 4 females (a ratio of 2.5:1). The mean age of onset of
Parkinsonism in these patients was calculated at 53 years of age. Parkinsonism in Wilson’s disease
patients was reported in six papers in which four (66.6%) described typical features while the remaining
two papers (33.3%) displayed atypical pictures. The mean age of onset in the patients described
was 46 years of age and a gender ratio 0.75:1 (three males and six females).
4. Discussion
Parkinsonian presentation in patients with metal storage disorders is an area of growing
interest. The number of publications identified in this study increases each decade. While only three
articles were published earlier than 1990, between the years 2010 to 2018, 29 papers were identified.
This demonstrates an increasing amount of research being conducted in this field and a growing
appreciation for a possible correlation between Parkinsonism and metal storage disorders.
The family of neurodegenerative brain iron accumulation (NBIA) disorders includes Pantothenate
kinase-associated neurodegeneration (PKAN), Aceruloplasminemia, beta-propeller protein-associated
neurodegeneration (BPAN), Kufor-Rakeb Syndrome, mitochondrial-membrane protein-associated
neurodegeneration (MPAN), neuroferritinopathy, and PLA2G6-associated neurodegeneration (PLAN).
Articles discussing all of these disorders were identified by our searches and described patients
displaying Parkinsonism. These all showed a similar phenotype with young average ages
of onset of Parkinsonism ranging from 13 years old (Kufor-Rakeb syndrome) to 61 years old
(neuroferritinopathy) and predominantly atypical Parkinsonian features. This reflects the similar
pathologies across the NBIA family of disorders. In all NBIAs, increased deposition of iron in brain
tissue is observed. It is unclear whether this deposition is the direct cause of neurodegeneration or if
it is simply a marker of the degeneration occurring as a result of some other pathological mechanism.
However, Parkinsonism as well as dystonia appears well documented across all NBIAs.
In line with our findings, PKAN is the most common NBIA accounting for roughly half of all
cases [12]. In the 11 publications describing PKAN, all papers described patients with atypical features
while three also described patients with typical Parkinsonism. The atypical features displayed in
these patients were a poor levodopa response [13–16], a lack of asymmetrical features [15,17–19],
or the presence of dystonia in addition to Parkinsonism [14,20–22] (Appendix B). In two publications,
pyramidal signs were also observed [19,23]. Recent research has established that Lewy body pathology
is not observed in PKAN, which may explain why atypical features of Parkinsonism are more
commonly seen [24]. Historical reports of patients with PKAN have found α-synuclein inclusions
in neurons [7,25]. However, Schneider et al. believe these patients may have been misdiagnosed
since these reports were published before gene identification was available for diagnosing PKAN [24].
They describe a recent series of genetically confirmed PKAN patients in which all lacked any evidence
of Lewy body pathology. This suggests a differing pathology is occurring in these patients. Our results
showing a high prevalence of atypical Parkinsonism in PKAN sufferers supports this hypothesis.
At the same time, the widespread presence of α-synuclein inclusions in the central nervous system
(CNS) tissue of PLAN patients is well documented [26,27], which indicates a potential pathological link
between PLAN and sporadic PD. The results from this review support this link with two of the three
publications describing patients with PLAN due to features of typical Parkinsonism [28,29]. In the one
paper describing atypical parkinsonism features in patients with PLAN, dystonia was present [30].
Hereditary haemochromatosis (HH) was also frequently identified in this systematic review.
Four papers reported typical Parkinsonism [31–34] while atypical features were described in
the remaining three papers. All papers were related to unresponsiveness to levodopa [35–37].
These reports of Parkinsonism and HH presenting concurrently indicate that research into iron
accumulation in the CNS tissue of HH patients may clarify the pathological link between HH and PD.
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The pathological processes and brain regions involved in HH are not well understood. In particular,
the location of iron accumulation in CNS tissue is poorly documented. Since Parkinson’s disease
treatments were reported to be ineffective in these patients and an atypical picture was observed,
it may be that a different area of the brain is affected. Further research is required in order to identify
how and where the iron accumulation occurs in order to draw further conclusions from this result.
Six publications described Parkinsonism in Wilson’s disease. It is well established that copper
deposition, as seen in Wilson’s disease patients, commonly has toxic effects in the brain, which leads
to severe neurological features [38,39]. How copper causes neuronal death is not well understood
even though it is generally accepted that the copper accumulates extracellularly and does not enter
neurons [38]. Within this group, four publications described typical Parkinsonism in Wilson’s
disease [40–43] and two described atypical parkinsonism [44,45]. Although Parkinsonism is a common
feature of neurologic Wilson’s disease [38,39], there is no evidence to suggest that Wilson’s disease
causes Lewy body pathology. Despite this, all of the Wilson’s Disease patients from this study
displayed levodopa responsiveness. This included two patients with atypical parkinsonism where
one had dystonia [44] and one had epilepsy [45]. As mitochondrial dysfunction plays a large
role in the pathophysiology of PD [1,2], the extracellular accumulation of copper in the CNS
may have the same effect on mitochondria within the neuron that it does within the hepatocytes.
Despite the similarities in clinical features and the response to levodopa, these patients’ demographics
differ significantly to those seen in the sporadic PD population, which is outlined by Rizek et al. [46].
The average age of onset of Parkinsonism in these Wilson’s disease patients was reported as 46 years
old, which is considerably younger than in the sporadic PD population (mean age 65 years
old). Furthermore, twice as many females as males were described as having Parkinsonism,
which differs greatly to the ratio of 1.5 males per females seen in the sporadic PD population.
However, since only nine patients were described, this is not a large enough population to draw
generalizable conclusions especially since the lack of α-synuclein pathology indicates the presence of
a different pathological process.
Despite previous research establishing that cigarette smoking is protective for PD [4], the smoking
status was not reported in any of the publications (Appendix B). Therefore, it was not possible to
investigate this in the current study. It would be pertinent to include the smoking status in the patient
demographics of all future publications describing PD or features of Parkinsonism.
The precise nature of the relationship between iron accumulation in patients with Parkinsonism
is not clear. Autopsy studies were excluded from this review since they offered retrospective details of
the clinical picture and the timelines were poorly outlined. However, they could yield some useful
findings in patients with metal storage disorders. Post mortem brain studies on patients with NBIAs
allows us to investigate the correlation between the quantity of iron and the severity of PD features.
Should this confirm that iron accumulation in the brain leads to the development of Parkinsonism,
it follows that treatments to reduce the CNS iron levels, or act as an iron chelator, could be developed
as an early treatment for patients with sporadic PD in order to delay the Parkinsonian features.
An important factor to consider when interpreting these results is the level and quality of evidence
available in the literature. The majority of the publications included were case reports and case series
that the Oxford Centre of Evidence-Based Medicine considers level 4 evidence [47]. However, due to
the rarity of these individual IEMs, this was the highest level of evidence available. Case reports can be
subject to bias and, although no formal bias assessment was conducted, a more favourable response
to levodopa or exaggeration of the severity of the features may have been reported. This was taken
into consideration when evaluating articles for inclusion and any paper describing a response less
than moderate to levodopa was classed as atypical.
5. Conclusions
In conclusion, the presence of Parkinsonism in metal storage disorders is an under reported topic.
Establishing the relationships between these conditions may clarify the pathological mechanisms of
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Parkinsonism. Therefore, it is a field of growing interest with the number of publications describing
patients with metal storage disorders displaying Parkinsonism growing substantially each decade.
This review has demonstrated the following:
1. There is evidence of Parkinsonism coexisting with metal storage disorders in particular
neurodegenerative brain iron accumulation disorders.
2. Patients with these metal storage disorders have an earlier age of onset of Parkinsonism
than sporadic PD patients, which suggests additional underlying pathological processes are
taking place. The ratio of males to females seen in many of these also differs significantly to
the sporadic PD population, which further indicates a differing pathogenesis.
3. Future research must be conducted at a higher level than individual case reports to better assess
the relationship between metal storage disorders and Parkinsonism. Cohort studies or case
control studies using large cohorts will lead to a reliable dataset. At the same time, research in
sporadic PD patients will identify whether any of the pathological mutations or processes are
involved in the disorders discussed in relation to the development of Parkinsonism.
4. Smoking status and ethnicity should be documented in all future studies of Parkinsonism since
Caucasian ethnicity is a large risk factor in sporadic PD while cigarette smoking appears to be
protective. Recording these demographics will allow for the investigation of their presence in
patients with metal storage disorders.
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Appendix A.
Search terms. Term A: Parkinson, Parkinson’s, Parkinsonism, Parkinsonism. Term B:
Aceruloplasminemia, Acrodermatitis, Bartter disease, BPAN, Calcium metabolism, CoPAN,
Copper metabolism, DiGeorge, Fahr, Hemochromatosis, Hereditary rickets, Iron metabolism,
Kufor-Rakeb syndrome, Magnesium metabolism, Menkes, Mitochondrial membrane protein-associated
neurodegeneration, Neurodegenerative brain iron accumulation, Neuroferritinopathy, PLAN,
PLA2G6-associated neurodegeneration, Phosphate metabolism, Pseudohypoparathyroidism,
Tumoral calcinosis, Vitamin D metabolism, Wilson, Woodhouse-Sakati syndrome, Zinc metabolism.
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Appendix B.
Table A1. Table showing the individual breakdown of the included publications. NA = Not Available.
Paper Type of Paper Condition Male/Female
Average Age at Onset of
Parkinsonism (years)
Ethnicity
Smoking
Status
Typical
Parkinsonism
Atypical
Parkinsonism
Parkinsonism Features
Alberca, R. et al.,
1987. [20]
Case report PKAN 1M/1F 27 NA NA X X
Female siblings: Typical features.
Male sibling: associated with dystonia.
Fast progression.
Batla, A. et al., 015. [48] Case report Neuroferritinopathy 1F 79 NA NA X Associated with dystonia.
Behrens, M.I. et al.,
2010. [49]
Case Series Kufor-Rakeb Syndrome 4M/1F NA Chilean NA X
Parkinsonian features in all five pts.
No tremor present. Supranuclear gaze
palsy in 4/5, poor L-dopa response
Bozi, M. et al.,
2009. [23]
Case report PKAN 1M 15 NA NA X
Mildly affected but associated with
pyramidal signs.
Chinnery, P.F. et al.,
2007. [50]
Cross-sectional
study
Neuroferritinopathy 3F NA
2 English,
1 French
NA X
Associated with dystonia in all three.
No tremor present.
Costello, D.J. et al.,
2004. [31]
Case report
Hereditary
Haemochromatosis
3M/1F 53 NA NA X
Four pts all with HH and IPD
diagnoses, classical signs. Good
L-dopa response.
Crosiers, D. et al.,
2011. [51]
case report Kufor-Rakeb syndrome 1M 10 Afghan NA X Associated with dystonia.
Czlonkowska, A. et al.,
2018. [40]
Cross-sectional
study
Wilson’s disease NA NA Polish NA X
Parkinsonism found in 11.3%
(6/53 pts).
Darling, A. et al.,
2017. [21]
Cross-sectional
study
PKAN 22M/25F NA NA NA X
Features of Parkinsonism displayed in
all 47 pts. Associated with Dystonia.
Demarquay, G. et al.,
2000. [35]
Case report
Hereditary
Haemochromatosis
2M/1F 56 NA NA X
Bradykinesia and rigidity on left side.
Poor L-dopa response.
Di Fonzo, A. et al.,
2007. [52]
Cross-sectional
study
Kufor-Rakeb Syndrome 3M NA NA NA X X
Features of Parkinsonism in all three
pts. Supranuclear gaze palsy
and hallucinations/psychotic episodes
in 1/3, psychotic episodes in 1/3,
and typical features in 1/3.
Diaz, N., 2013. [13] Case report PKAN 1F NA NA NA X
L-dopa unresponsive, symmetrical
features.
Eiberg, H. et al.,
2012. [53]
Case report Kufor-Rakeb Syndrome 1M 12 NA NA X
Supranuclear gaze palsy, cognitive
impairment, and hallucinations.
Evans, B.K. & Donley,
D.K., 1988. [54]
Case report Pseudohypoparathyroidism 1F 20 NA NA X
Rest tremor and bradykinesia with
mental retardation.
Fekete, R., 2012. [55] Case report NBIA, unknown type 1M 73 NA NA X
Typical features. Poor
L-dopa response but dystonia present
upon removal of L-dopa.
Fonderico, M. et al.,
2017. [56]
Case report BPAN 1F 26 NA NA X Mild typical parkinsonism.
Gasca-Salas, C. et al.,
2017. [44]
Case report Wilson’s Disease 1F 38 NA NA X
Tremor, clumsiness, rigidity,
and dystonia in left arm. Good
L-dopa response.
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Table A1. Cont.
Paper Type of Paper Condition Male/Female
Average Age at Onset of
Parkinsonism (years)
Ethnicity
Smoking
Status
Typical
Parkinsonism
Atypical
Parkinsonism
Parkinsonism Features
Giri, A. et al., 2016. [28] Case report PLAN 1F 27 NA NA X Typical Features, PD diagnosis.
Girotra, T., Mahajan, A. &
Sidiropoulos, C.,
2017. [32]
Case report
Hereditary
Haemochromatosis
1M 41 Caucasian NA X
Typical features, mild but clear
response to L-dopa.
Gondim, F. de A.A. et al.,
2014. [41]
Case Series Wilson’s disease 2M/2F 28 Brazil NA X
Four pts with typical features, all
responded well to L-dopa.
Gore, E. et al., 2016. [57] Case report MPAN 1M 35 Kuwaiti NA X Early behavioural change.
Hayflick, S.J. et al.,
2013. [58]
Cohort study BPAN 3M/18F 25 NA NA X
Developmental delay, dystonia,
and parkinsonism. L-dopa responsive.
Hermann, A. et al.,
2017. [59]
Case report BPAN 1F 24 German NA X
Supranuclear gaze palsy, dystonia,
and no L-dopa response.
Ichinose, Y. et al.,
2014. [60]
Case report BPAN 1F 30 NA NA X Associated with dystonia.
Kim, Y.J. et al.,
2015. [30]
Case Series PLAN 1M/1F 14 Korean NA X Associated with dystonia in 2/2 pts.
Klysz, B., Skowronska, M.
& Kmiec, T., 2014. [61]
Case report MPAN 1F 15 NA NA X
Chorea, dystonia, and psychological
manifestations.
Kumar, N. et al.,
2016. [33]
Case Series
Hereditary
Haemochromatosis
2M/1F 59
1 Irish-Portuguese,
1 Scottish,
1 unknown
NA X
Parkinsonian signs in three pts. One
responded well to L-dopa, one not
treated.
Lee, C.-H. et al.,
2013. [17]
Case report PKAN 2M 20 Taiwanese NA X X
Typical parkinsonism in one pt though
onset at 18. Bilateral features in
the other.
Lee, J.-H. et al., 2016. [14]
Cross-sectional
study
PKAN 6M 36 NA NA X
Poor response to L-dopa in all.
Associated with dystonia in 4/6 pts,
isolated parkinsonism in 2/6 pts.
Mak, C.M. et al.,
2011. [18]
Case report PKAN 1M 27 Hong Kong NA X Bilateral features.
Ni, W. et al., 2016. [62] Case report Neuroferritinopathy 1F 44 NA NA X
No response to L-dopa, pyramidal
signs.
Nielsen, J.E., Jensen, L.N.
& Krabbe, K., 1995. [34]
Case report
Hereditary
Haemochromatosis
1M 29 NA NA X
Typical PD features, immediate
improvement with L-dopa.
Nishioka, K. et al.,
2015. [63]
Cross-sectional
study
BPAN 7F 32 NA NA X
Cognitive dysfunction as presenting
symptom in all seven. Otherwise
typical parkinsonism.
L-dopa responsive.
Oder, W. et al.,
1991. [42]
Cross-sectional
study
Wilson’s Disease NA NA NA NA X
8/25 pts with parkinsonian features.
Bradykinesia, resting tremor present.
Olgiati, S. et al.,
2017. [64]
Cross-sectional
study
MPAN NA NA NA NA X
9/15 pts with parkinsonian features.
Cognitive impairment and pyramidal
signs seen.
Pearson, D.W. et al.,
1981. [65]
Case report Pseudohypoparathyroidism 1M 58 NA NA X
Typical PD features. Very fast disease
progression.
Pestana Knight, E.M.,
Gilman, S. & Selwa, L.,
2009. [45]
Case report Wilson’s Disease 1M 55 NA NA X
Typical PD features associated with
epilepsy.
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Table A1. Cont.
Paper Type of Paper Condition Male/Female
Average Age at Onset of
Parkinsonism (years)
Ethnicity
Smoking
Status
Typical
Parkinsonism
Atypical
Parkinsonism
Parkinsonism Features
Racette, B.A. et al.,
2001. [15]
Case report PKAN 1F 60 NA NA X
Bilateral features, no response to
L-dopa.
Rohani, M. et al.,
2017. [66]
Case report Fahr disease 1F 50 NA NA X
Typical L-dopa responsive
parkinsonism.
Rosana, A. & La Rosa, L.,
2007. [36]
Case report
Hereditary
Haemochromatosis
1M 58 NA NA X No response to L-dopa.
Sakarya, A., Oncu, B. &
Elibol, B., 2012. [19]
Case report PKAN 1M 16 NA NA X
Early severe cognitive impairment,
bilateral onset, pyramidal features.
Scale, T. et al.,
2014. [67]
Case report Fahr Disease 1M 62 NA NA X No response to L-dopa.
Schneider, S.A. et al.,
2010. [12]
Case report Kufor-Rakeb syndrome 1M 16 Pakistan NA X Associated with dystonia.
Sechi, G. et al., 2007. [43] Case report Wilson’s disease 3F 70 NA NA X
Very late onset L-dopa responsive
parkinsonism.
Seo, J.-H., Song, S.-K. &
Lee, P.H., 2009. [16]
Case report PKAN 1M 35 NA NA X No response to L-dopa.
Song, C.-Y. et al.,
2017. [68]
Case report Pseudohypoparathyroidism 1F 52 NA NA X Very fast disease progression.
Thomas, M., Hayflick, S.J.
& Jankovic, J., 2004. [22]
Cross-sectional
study
PKAN 14M/8F 35 NA NA X X
Typical parkinsonism seen, though
clinical features not defined.
Associated with dystonia in 4/22 pts.
Vroegindeweij, L.H.P. et
al., 2017. [69]
Case Series Aceruloplasminemia 4M/1F NA
4 Dutch,
1 Italian
NA
Parkinsonian features in all pts.
Associated with cognitive decline
and cerebellar features in all pts.
Williams, S. et al.,
2013. [37]
Case report
Hereditary
Haemochromatosis
1F 60 Caucasian NA X
Short disease course, early autonomic
involvement, no L-dopa response.
Xie, F. et al., 2015. [29] Case report PLAN 2M 34 NA NA X
Typical features, good
L-dopa response.
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